Offline Showroom in USA
Post Offer Free

Gold Index: 82941

You are here: home  > Pharmaceutical Chemicals API  > Endocrine Drugs API  > Sitagliptin phosphate monohydrate CAS 654671-77-9 Sitagliptin Phosphate.H2O

Sitagliptin phosphate monohydrate CAS 654671-77-9 Sitagliptin Phosphate.H2O 

Payment Terms: T/T,L/C,WU 
Place of Origin: Sichuan, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C16H20F6N5O6P
Production Capacity: 150 Ton/Year
Delivery Date: within 7 days
CAS: 654671-77-9
Alias: Januvia
Means of Transport: Ocean,Land
Packing: According to the request of...
Appearance: White crystalline powder
Molecular Formula: C16H20F6N5O6P
Molecular weight: 523.3240802

To lift the body's own's ability to reduce high blood sugar level.

Sitagliptin phosphate monohydrate (CAS: 654671-77-9)

Acid west his dean was first developed by Merck, Germany won the U.S. food and drug administration approved for the treatment of type 2 diabetes dipeptide base peptidase Ⅳ (DDP - 4) inhibitor medicine, is a new type of diabetes, can increase the body's own ability to reduce high blood sugar levels, inhibit the enzyme activity and relatively improve shortness of naturally occurring intestinal insulin, including sample glucagon peptide 1 promote insulin and glucose dependence peptide levels, increased insulin production is triggering the pancreas and the liver to stop glucose production, and finally the clinical effect of lowering blood sugar concentration. The characteristic of this product is in stimulating insulin secretion, at the same time can reduce hungry feeling, and will not put on weight, also won't hypoglycemia and edema occur, suitable for diabetic patients with poor blood sugar control and frequent hypoglycemia. 552 cases of clinically mild-to-moderate patients with type 2 diabetes, take a daily phosphate west he listed, take 100 milligrams, 12 weeks after can reduce glycated hemoglobin 0.6% - 0.6%


This drug for dipeptide peptidase 4 (DPP - 4) depressants, by protecting endogenous im fall blood sugar, and enhance its role and control blood sugar levels. Glucose dependence on promoting insulin releasing peptide (GIP) and glucagon peptide 1 (glp-1), as for dietary intake and release of intestinal fall blood sugar. Glp-1 and GIP can increase insulin synthesis and through intracellular signaling pathways from the release of the islet beta cells, glp-1 can reduce islet alpha cells glucagon secretion, reduce hepatic glucose production. But glp-1 and GIP vetted by DPP - 4 quick metabolism, leading to loss of its effect on promoting insulin. This drug inhibits the degradation of im fall blood sugar, the DPP - 4, so it can enhance the function of glp-1 and GIP, increase insulin release and reduce the cycle of glucagon levels (this role in glucose dependencies). This drug is selective inhibition of DPP - 4, the DPP - 8 or DPP - 9 no inhibitory activity. 2. The pharmacokinetic This drug is 1-4 hours after oral reach peak blood drug concentrations of 950 nmol, area under the curve tendency for 8.52 h, absolute bioavailability of about 87%, and protein

Application:To lift the body's own's ability to reduce high blood sugar level.

skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on

Company Info


Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: